ReviewRecent advances in drug delivery and formulation2025
Management of Rheumatoid Arthritis By Development of Nanocarriers and their Significance Over Conventional Dosage Forms.
Review in Recent advances in drug delivery and formulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Th17/Treg axis: a key to understanding and treating autoimmune disorders.Open life sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid Arthritis is one of the most common auto-immune diseases that cause inflammation. It is characterized by pain, stiffness, tenderness, and swelling in joints, which may even lead to heart, lungs, or brain-related problems where age is the major factor involved, as around 55% older adults have been affected by it. Treatments including non-steroidal anti- inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs) etc., that are modified and formulated as nanocarriers for enhanced bioavailability, majorly aim at enhancing the rate and extent of drug reaching the bloodstream such as solid-lipid nanoparticles, liposomes, polymeric- micelles, polymeric nanoparticles etc. are used in the management of rheumatoid arthritis.
methodsThe following tools (Pubmed, Scopus, Google search engine, Google Scholar, Medline Search Engine, Elsevier) were used in the literature search.
resultsThrough the literature review, the development of nanocarrier shows a promising approach in the management of rheumatoid arthritis as compared to the conventional drug treatment such as biologic agents and non-steroidal anti-inflammatory drugs etc. Conclusion: Rheumatoid Arthritis is a condition that occurs when the immune system, which normally helps to protect the body from infection and disease, attacks its own tissues. The disease causes pain, swelling as well as loss of function in joints. Therefore, life-long management is required by reducing the dose frequency and dosage regimen, which can be effectively approached by the development of a nano-carrier for significant drug uptake and low toxicity.
Indexed as
Identifiers
40495597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.